Biotech Values

[DewDiligence]

ARIA—I like this design as it may reduce the risk in terms of gaining approval in one or more cohorts as opposed to the all or none that is more typical in registration trials.

There would seem to be only two (overlapping) cohorts where there might be enough data to get subgroup-specific FDA approval: i) chronic phase; and ii) T315I+.